课题基金 / 基金详情

Alpha-synuclein RNAi in a model of sporadic Parkinson's disease

Alpha-synuclein RNAi in a model of sporadic Parkinson's disease
散发性帕金森病模型中的 α-突触核蛋白 RNAi
批准号:
8195861
负责人:
Edward Alan Burton
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-10-01 至 2012-09-30

项目摘要

项目成果

Edward Alan Burton的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 帕金森氏病(PD)是导致退伍军人发病的重要原因。当前 治疗不能防止帕金森病进展导致的残疾。了解 因此,研究常见的散发性帕金森病的发病机制是一个紧迫的目标,以便 可以开发适当的治疗干预措施。多条趋同的证据表明 线粒体呼吸链功能受损和突触核蛋白异常 新陈代谢可能是散发性帕金森病的中心。尽管体外证据表明 突触核蛋白和线粒体之间的双向相互作用,目前尚不清楚这些 多巴胺能神经元变性是帕金森病的基础。在这个提案中,我们将利用最近的两个 为了询问突触核蛋白是否是多巴胺能中的一个重要因素的技术进展 在体内发生的神经元变性,对部分系统性线粒体损伤的反应, 在散发性帕金森病中发现的类型。首先,我们开发了新腺相关病毒(AAV)载体 表达针对内源性大鼠突触核蛋白转录本的短发夹状RNA(ShRNA),并具有 优化的AAV载体体内递送到大鼠黑质,允许调制? 突触核蛋白在大鼠黑质纹状体投射中的表达。第二,我们开发了一部小说 散发性帕金森病模型,其中部分系统线粒体复合体I损伤,每天 经腹膜腔注射鱼藤酮,可导致黑质高度重复性损害,包括 形成明显的突触核蛋白免疫反应包涵体,类似于路易小体和 多巴胺能神经元变性。因为它可重复地概括了多个相关 以散发性帕金森病为特征的腹膜腔内鱼藤酮模型将是唯一的 适用于确定-突触核蛋白是否代表血管内皮细胞瘤发病中的关键介质 这种疾病。在拟议的实验中,我们将检查行为、神经化学和 成年动物中突触核蛋白基因敲除的组织学效应(目标1)。我们从数据中预测 在突触核蛋白基因敲除的小鼠中,多巴胺能神经传递会有轻微的减少。 然而,生殖系Null中可能存在的发育代偿/适应性变化 突变将不会出现在成人身上的这些实验中;因此,研究结果可能会 与鼠标击倒中报告的不同。这些数据将构成解释的基础 随后的实验,并将告知潜在安全问题复杂化的可能性 神经保护策略旨在调节成人大脑中突触核蛋白的表达。我们会 接下来询问?-突触核蛋白敲除是否对形成?-突触核蛋白包涵体具有保护作用, 慢性鱼藤酮暴露后的神经行为缺陷和黑质细胞丢失(目标2)。我们 假设黑质病变的发病机制依赖于 线粒体和突触核蛋白,从而减少内源性突触核蛋白的表达 在shRNA载体转导后,将改善病理,导致显著保存 多巴胺能功能。这项实验将揭示减少细胞数量的可能效果。 突触核蛋白水平或靶向功能异常的突触核蛋白在防止帕金森病进展中的作用。 总而言之,这些研究将确定体内两种主要疾病之间相互作用的重要性。 帕金森病在神经变性发病机制中的特征性异常,并将决定 突触核蛋白是否为常见散发性脑脊髓瘤神经保护的有效治疗靶点 帕金森氏症的一种。
英文摘要
Abstract Parkinson's disease (PD) is an important cause of morbidity in the Veteran population. Current treatments do not prevent disability resulting from progression of PD. Understanding the pathogenesis of the common sporadic form of PD is therefore an urgent objective, in order that appropriate therapeutic interventions can be developed. Multiple convergent lines of evidence suggest that impairment of mitochondrial respiratory chain function and abnormalities of ¿-synuclein metabolism may be central to sporadic PD. Although evidence in vitro suggests the presence of bidirectional interactions between ¿-synuclein and the mitochondrion, it is unclear whether these underlie dopaminergic neuronal degeneration in PD. In this proposal, we will exploit two recent technical advances in order to ask whether ¿-synuclein is an important factor in the dopaminergic neuronal degeneration that occurs in vivo in response to partial systemic mitochondrial impairment, of the type found in sporadic PD. First, we have developed novel adeno-associated virus (AAV) vectors that express short hairpin RNA (shRNA) targeting the endogenous rat ¿-synuclein transcript, and have optimized in vivo delivery of AAV vectors to the rat substantia nigra, allowing modulation of ¿- synuclein expression in the rat nigro-striatal projection in vivo. Second, we have developed a novel model of sporadic PD, in which partial systemic mitochondrial complex I impairment, induced by daily intraperitoneal rotenone delivery, causes a highly reproducible lesion of the substantia nigra, including formation of prominent ¿-synuclein immunoreactive inclusions resembling Lewy bodies and degeneration of dopaminergic neurons. Since it reproducibly recapitulates multiple relevant abnormalities characteristic of sporadic PD, the intraperitoneal rotenone model will be uniquely suitable for determination of whether ¿-synuclein represents a critical mediator in the pathogenesis of the disease. In the proposed experiments, we will examine the behavioral, neurochemical and histological effects of ¿-synuclein knockdown in an adult animal (objective 1). We anticipate from data in ¿-synuclein knockout mice that there will be a subtle reduction in dopaminergic neurotransmission. However, developmental compensatory/adaptive changes that may be present in germline null mutants will be absent from these experiments in adults; consequently, it is possible that findings will be different to those reported in mouse knockouts. These data will form a basis for interpretation of subsequent experiments, and will inform on the likelihood of potential safety issues complicating neuroprotective strategies directed at modulation of ¿-synuclein expression in the adult brain. We will next ask whether ¿-synuclein knockdown is protective against the formation of ¿-synuclein inclusions, neurobehavioral deficits and nigral cell loss after chronic rotenone exposure (objective 2). We hypothesize that pathogenesis of the nigral lesion is dependent on a key interaction between mitochondria and ¿-synuclein, and consequently that reduction of endogenous ¿-synuclein expression following shRNA vector transduction will ameliorate pathology, resulting in significant preservation of dopaminergic function. This experiment will inform on the possible efficacy of reducing cellular ¿- synuclein levels or targeting abnormal functions of ¿-synuclein in preventing PD progression. Together, these studies will determine the importance of an interaction in vivo between two major characteristic abnormalities of PD in the pathogenesis of neurodegeneration, and will determine whether ¿-synuclein represents a valid therapeutic target for neuroprotection in the common sporadic form of Parkinson's disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
A Phenotype-Optimized Zebrafish Model of Progressive Supranuclear Palsy
A Phenotype-Optimized Zebrafish Model of Progressive Supranuclear Palsy
Functional evaluation of genes adjacent to risk-modulating SNPs in the pathogenesis of PSP
Role of BET proteins in neuroinflammation in tauopathy
  • 批准号:
    10512035
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2016
  • 负责人:
    Edward Alan Burton
  • 依托单位:
海外基金